Section Arrow
Quote
SHPH.NASDAQ
- Shuttle Pharmaceuticals Holdings Inc
Quotes are at least 15-min delayed:2026/05/19 14:33 EDT
Regular Hours
Last
 0.5934
-0.0266 (-4.29%)
Day High 
0.61669 
Prev. Close
0.62 
1-M High
1.14 
Volume 
120.89K 
Bid
0.5934
Ask
0.61
Day Low
0.59 
Open
0.6064 
1-M Low
0.5946 
Market Cap 
3.44M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.69 
20-SMA 0.82 
50-SMA 0.84 
52-W High 6.1925 
52-W Low 0.5003 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.16/--
Enterprise Value
3.59M
Balance Sheet
Book Value Per Share
0.41
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
INMInMed Pharmaceuticals Inc1.7097+1.029+151.17%-- 
HIMSHims & Hers Health22.49+0.2+0.90%-- 
AKBAAkebia Therapeutics0.8844-0.1256-12.44%-- 
SBFMSunshine Biopharma Inc0.4406-0.0694-13.61%-- 
VTRSViatris16.135-0.365-2.21%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.